Arch Therapeutics, Inc.
Arch Therapeutics, Inc. (ARTH) Stock Competitors & Peer Comparison
See (ARTH) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARTH | $0.00 | +0.00% | 444 | -0.00 | -$1.01 | N/A |
| NONOF | $48.68 | +1.43% | 213.3B | 13.16 | $3.65 | +3.43% |
| CSLLY | $86.67 | -0.43% | 164.7B | 31.27 | $2.72 | +1.56% |
| CMXHF | $178.56 | +3.21% | 86.5B | 33.31 | $5.36 | +1.55% |
| UCBJY | $106.75 | -0.59% | 40.8B | 27.39 | $3.92 | +0.74% |
| UCBJF | $207.00 | -5.82% | 40.6B | 27.24 | $7.85 | +0.74% |
| ARGNF | $547.60 | +0.00% | 33.5B | 27.85 | $19.66 | N/A |
| ODTC | $22,005.00 | +29.44% | 24.1B | 1.07 | $20,580.00 | N/A |
| IVBXF | $12.05 | -4.48% | 20.6B | -1207.00 | -$0.01 | N/A |
| SBMFF | $0.95 | +0.00% | 17B | 95.30 | $0.01 | +0.94% |
Stock Comparison
ARTH vs NONOF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, NONOF has a market cap of 213.3B. Regarding current trading prices, ARTH is priced at $0.00, while NONOF trades at $48.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas NONOF's P/E ratio is 13.16. In terms of profitability, ARTH's ROE is +0.89%, compared to NONOF's ROE of +0.81%. Regarding short-term risk, ARTH is more volatile compared to NONOF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check NONOF's competition here
ARTH vs CSLLY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CSLLY has a market cap of 164.7B. Regarding current trading prices, ARTH is priced at $0.00, while CSLLY trades at $86.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CSLLY's P/E ratio is 31.27. In terms of profitability, ARTH's ROE is +0.89%, compared to CSLLY's ROE of +0.26%. Regarding short-term risk, ARTH is more volatile compared to CSLLY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CSLLY's competition here
ARTH vs CMXHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CMXHF has a market cap of 86.5B. Regarding current trading prices, ARTH is priced at $0.00, while CMXHF trades at $178.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CMXHF's P/E ratio is 33.31. In terms of profitability, ARTH's ROE is +0.89%, compared to CMXHF's ROE of +0.15%. Regarding short-term risk, ARTH is more volatile compared to CMXHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CMXHF's competition here
ARTH vs UCBJY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, UCBJY has a market cap of 40.8B. Regarding current trading prices, ARTH is priced at $0.00, while UCBJY trades at $106.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas UCBJY's P/E ratio is 27.39. In terms of profitability, ARTH's ROE is +0.89%, compared to UCBJY's ROE of +0.03%. Regarding short-term risk, ARTH is more volatile compared to UCBJY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check UCBJY's competition here
ARTH vs UCBJF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, UCBJF has a market cap of 40.6B. Regarding current trading prices, ARTH is priced at $0.00, while UCBJF trades at $207.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas UCBJF's P/E ratio is 27.24. In terms of profitability, ARTH's ROE is +0.89%, compared to UCBJF's ROE of +0.03%. Regarding short-term risk, ARTH is more volatile compared to UCBJF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check UCBJF's competition here
ARTH vs ARGNF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ARGNF has a market cap of 33.5B. Regarding current trading prices, ARTH is priced at $0.00, while ARGNF trades at $547.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ARGNF's P/E ratio is 27.85. In terms of profitability, ARTH's ROE is +0.89%, compared to ARGNF's ROE of +0.16%. Regarding short-term risk, ARTH is more volatile compared to ARGNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ARGNF's competition here
ARTH vs ODTC Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ODTC has a market cap of 24.1B. Regarding current trading prices, ARTH is priced at $0.00, while ODTC trades at $22,005.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ODTC's P/E ratio is 1.07. In terms of profitability, ARTH's ROE is +0.89%, compared to ODTC's ROE of +0.07%. Regarding short-term risk, ARTH is more volatile compared to ODTC. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ODTC's competition here
ARTH vs IVBXF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, IVBXF has a market cap of 20.6B. Regarding current trading prices, ARTH is priced at $0.00, while IVBXF trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas IVBXF's P/E ratio is -1207.00. In terms of profitability, ARTH's ROE is +0.89%, compared to IVBXF's ROE of -0.01%. Regarding short-term risk, ARTH is more volatile compared to IVBXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check IVBXF's competition here
ARTH vs SBMFF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SBMFF has a market cap of 17B. Regarding current trading prices, ARTH is priced at $0.00, while SBMFF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SBMFF's P/E ratio is 95.30. In terms of profitability, ARTH's ROE is +0.89%, compared to SBMFF's ROE of +0.11%. Regarding short-term risk, ARTH is more volatile compared to SBMFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SBMFF's competition here
ARTH vs SBHMY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SBHMY has a market cap of 16.7B. Regarding current trading prices, ARTH is priced at $0.00, while SBHMY trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SBHMY's P/E ratio is 64.31. In terms of profitability, ARTH's ROE is +0.89%, compared to SBHMY's ROE of +0.11%. Regarding short-term risk, ARTH is more volatile compared to SBHMY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SBHMY's competition here
ARTH vs WXIBF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, WXIBF has a market cap of 16.5B. Regarding current trading prices, ARTH is priced at $0.00, while WXIBF trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas WXIBF's P/E ratio is 36.77. In terms of profitability, ARTH's ROE is +0.89%, compared to WXIBF's ROE of +0.06%. Regarding short-term risk, ARTH is more volatile compared to WXIBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check WXIBF's competition here
ARTH vs WXXWY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, WXXWY has a market cap of 15.9B. Regarding current trading prices, ARTH is priced at $0.00, while WXXWY trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas WXXWY's P/E ratio is 35.59. In terms of profitability, ARTH's ROE is +0.89%, compared to WXXWY's ROE of +0.06%. Regarding short-term risk, ARTH is more volatile compared to WXXWY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check WXXWY's competition here
ARTH vs GNMSF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, GNMSF has a market cap of 13.7B. Regarding current trading prices, ARTH is priced at $0.00, while GNMSF trades at $222.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas GNMSF's P/E ratio is 13.04. In terms of profitability, ARTH's ROE is +0.89%, compared to GNMSF's ROE of +0.26%. Regarding short-term risk, ARTH is more volatile compared to GNMSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check GNMSF's competition here
ARTH vs TRSBF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, TRSBF has a market cap of 10.2B. Regarding current trading prices, ARTH is priced at $0.00, while TRSBF trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas TRSBF's P/E ratio is 35.83. In terms of profitability, ARTH's ROE is +0.89%, compared to TRSBF's ROE of +0.11%. Regarding short-term risk, ARTH is more volatile compared to TRSBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check TRSBF's competition here
ARTH vs AKBLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, AKBLF has a market cap of 6.4B. Regarding current trading prices, ARTH is priced at $0.00, while AKBLF trades at $28.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas AKBLF's P/E ratio is 44.54. In terms of profitability, ARTH's ROE is +0.89%, compared to AKBLF's ROE of +0.18%. Regarding short-term risk, ARTH is more volatile compared to AKBLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check AKBLF's competition here
ARTH vs AAVXF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, AAVXF has a market cap of 5.5B. Regarding current trading prices, ARTH is priced at $0.00, while AAVXF trades at $70.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas AAVXF's P/E ratio is -21.39. In terms of profitability, ARTH's ROE is +0.89%, compared to AAVXF's ROE of -2.11%. Regarding short-term risk, ARTH is more volatile compared to AAVXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check AAVXF's competition here
ARTH vs ABCZF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ABCZF has a market cap of 5.1B. Regarding current trading prices, ARTH is priced at $0.00, while ABCZF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ABCZF's P/E ratio is 2225.00. In terms of profitability, ARTH's ROE is +0.89%, compared to ABCZF's ROE of -0.01%. Regarding short-term risk, ARTH is more volatile compared to ABCZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ABCZF's competition here
ARTH vs INCPF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, INCPF has a market cap of 4.9B. Regarding current trading prices, ARTH is priced at $0.00, while INCPF trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas INCPF's P/E ratio is -108.67. In terms of profitability, ARTH's ROE is +0.89%, compared to INCPF's ROE of -0.05%. Regarding short-term risk, ARTH is more volatile compared to INCPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check INCPF's competition here
ARTH vs LABFF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, ARTH is priced at $0.00, while LABFF trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas LABFF's P/E ratio is 28.95. In terms of profitability, ARTH's ROE is +0.89%, compared to LABFF's ROE of +0.38%. Regarding short-term risk, ARTH is more volatile compared to LABFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check LABFF's competition here
ARTH vs TLPPF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, TLPPF has a market cap of 4.4B. Regarding current trading prices, ARTH is priced at $0.00, while TLPPF trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas TLPPF's P/E ratio is 145.00. In terms of profitability, ARTH's ROE is +0.89%, compared to TLPPF's ROE of +0.14%. Regarding short-term risk, ARTH is more volatile compared to TLPPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check TLPPF's competition here
ARTH vs GNNSF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, GNNSF has a market cap of 4.3B. Regarding current trading prices, ARTH is priced at $0.00, while GNNSF trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas GNNSF's P/E ratio is -25.00. In terms of profitability, ARTH's ROE is +0.89%, compared to GNNSF's ROE of -0.06%. Regarding short-term risk, ARTH is more volatile compared to GNNSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check GNNSF's competition here
ARTH vs CAMRF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CAMRF has a market cap of 4.2B. Regarding current trading prices, ARTH is priced at $0.00, while CAMRF trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CAMRF's P/E ratio is 56.35. In terms of profitability, ARTH's ROE is +0.89%, compared to CAMRF's ROE of +0.17%. Regarding short-term risk, ARTH is more volatile compared to CAMRF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CAMRF's competition here
ARTH vs ZLDPF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ZLDPF has a market cap of 3.9B. Regarding current trading prices, ARTH is priced at $0.00, while ZLDPF trades at $54.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ZLDPF's P/E ratio is -20.07. In terms of profitability, ARTH's ROE is +0.89%, compared to ZLDPF's ROE of -0.13%. Regarding short-term risk, ARTH is more volatile compared to ZLDPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ZLDPF's competition here
ARTH vs REGMF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, REGMF has a market cap of 3.1B. Regarding current trading prices, ARTH is priced at $0.00, while REGMF trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas REGMF's P/E ratio is -13.32. In terms of profitability, ARTH's ROE is +0.89%, compared to REGMF's ROE of -0.48%. Regarding short-term risk, ARTH is more volatile compared to REGMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check REGMF's competition here
ARTH vs SHJBF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SHJBF has a market cap of 2.9B. Regarding current trading prices, ARTH is priced at $0.00, while SHJBF trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SHJBF's P/E ratio is -10.94. In terms of profitability, ARTH's ROE is +0.89%, compared to SHJBF's ROE of -0.27%. Regarding short-term risk, ARTH is more volatile compared to SHJBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SHJBF's competition here
ARTH vs BVNKF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BVNKF has a market cap of 2.8B. Regarding current trading prices, ARTH is priced at $0.00, while BVNKF trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BVNKF's P/E ratio is 13.72. In terms of profitability, ARTH's ROE is +0.89%, compared to BVNKF's ROE of +0.12%. Regarding short-term risk, ARTH is more volatile compared to BVNKF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BVNKF's competition here
ARTH vs BVNRY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BVNRY has a market cap of 2.8B. Regarding current trading prices, ARTH is priced at $0.00, while BVNRY trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BVNRY's P/E ratio is 13.90. In terms of profitability, ARTH's ROE is +0.89%, compared to BVNRY's ROE of +0.12%. Regarding short-term risk, ARTH is more volatile compared to BVNRY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BVNRY's competition here
ARTH vs TKBIF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, TKBIF has a market cap of 2.8B. Regarding current trading prices, ARTH is priced at $0.00, while TKBIF trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas TKBIF's P/E ratio is 18.71. In terms of profitability, ARTH's ROE is +0.89%, compared to TKBIF's ROE of N/A. Regarding short-term risk, ARTH is more volatile compared to TKBIF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check TKBIF's competition here
ARTH vs MPSYF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, MPSYF has a market cap of 2.8B. Regarding current trading prices, ARTH is priced at $0.00, while MPSYF trades at $73.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas MPSYF's P/E ratio is -12.13. In terms of profitability, ARTH's ROE is +0.89%, compared to MPSYF's ROE of -1.84%. Regarding short-term risk, ARTH is more volatile compared to MPSYF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check MPSYF's competition here
ARTH vs ONTTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ONTTF has a market cap of 2.5B. Regarding current trading prices, ARTH is priced at $0.00, while ONTTF trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ONTTF's P/E ratio is -12.57. In terms of profitability, ARTH's ROE is +0.89%, compared to ONTTF's ROE of -0.27%. Regarding short-term risk, ARTH is more volatile compared to ONTTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ONTTF's competition here
ARTH vs GENSF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, GENSF has a market cap of 2.2B. Regarding current trading prices, ARTH is priced at $0.00, while GENSF trades at $33.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas GENSF's P/E ratio is -416.12. In terms of profitability, ARTH's ROE is +0.89%, compared to GENSF's ROE of +0.01%. Regarding short-term risk, ARTH is more volatile compared to GENSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check GENSF's competition here
ARTH vs ASPHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ASPHF has a market cap of 2.2B. Regarding current trading prices, ARTH is priced at $0.00, while ASPHF trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ASPHF's P/E ratio is -32.36. In terms of profitability, ARTH's ROE is +0.89%, compared to ASPHF's ROE of -0.70%. Regarding short-term risk, ARTH is more volatile compared to ASPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ASPHF's competition here
ARTH vs MEOBF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, MEOBF has a market cap of 1.9B. Regarding current trading prices, ARTH is priced at $0.00, while MEOBF trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas MEOBF's P/E ratio is -15.10. In terms of profitability, ARTH's ROE is +0.89%, compared to MEOBF's ROE of -0.15%. Regarding short-term risk, ARTH is more volatile compared to MEOBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check MEOBF's competition here
ARTH vs GLPGF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, GLPGF has a market cap of 1.9B. Regarding current trading prices, ARTH is priced at $0.00, while GLPGF trades at $28.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas GLPGF's P/E ratio is -5.64. In terms of profitability, ARTH's ROE is +0.89%, compared to GLPGF's ROE of -0.06%. Regarding short-term risk, ARTH is more volatile compared to GLPGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check GLPGF's competition here
ARTH vs BRCTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BRCTF has a market cap of 1.7B. Regarding current trading prices, ARTH is priced at $0.00, while BRCTF trades at $19.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BRCTF's P/E ratio is 18.25. In terms of profitability, ARTH's ROE is +0.89%, compared to BRCTF's ROE of +0.77%. Regarding short-term risk, ARTH is more volatile compared to BRCTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BRCTF's competition here
ARTH vs BIESF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BIESF has a market cap of 1.6B. Regarding current trading prices, ARTH is priced at $0.00, while BIESF trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BIESF's P/E ratio is -44.44. In terms of profitability, ARTH's ROE is +0.89%, compared to BIESF's ROE of +0.05%. Regarding short-term risk, ARTH is more volatile compared to BIESF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BIESF's competition here
ARTH vs PHMMF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PHMMF has a market cap of 1.6B. Regarding current trading prices, ARTH is priced at $0.00, while PHMMF trades at $91.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PHMMF's P/E ratio is 70.17. In terms of profitability, ARTH's ROE is +0.89%, compared to PHMMF's ROE of +0.10%. Regarding short-term risk, ARTH is more volatile compared to PHMMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PHMMF's competition here
ARTH vs CSBTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CSBTF has a market cap of 1.5B. Regarding current trading prices, ARTH is priced at $0.00, while CSBTF trades at $36.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CSBTF's P/E ratio is -291.54. In terms of profitability, ARTH's ROE is +0.89%, compared to CSBTF's ROE of -0.15%. Regarding short-term risk, ARTH is more volatile compared to CSBTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CSBTF's competition here
ARTH vs PPTDF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PPTDF has a market cap of 1.4B. Regarding current trading prices, ARTH is priced at $0.00, while PPTDF trades at $11.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PPTDF's P/E ratio is 13.91. In terms of profitability, ARTH's ROE is +0.89%, compared to PPTDF's ROE of +0.26%. Regarding short-term risk, ARTH is more volatile compared to PPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PPTDF's competition here
ARTH vs NURPF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, NURPF has a market cap of 1.4B. Regarding current trading prices, ARTH is priced at $0.00, while NURPF trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas NURPF's P/E ratio is 15.49. In terms of profitability, ARTH's ROE is +0.89%, compared to NURPF's ROE of +0.49%. Regarding short-term risk, ARTH is more volatile compared to NURPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check NURPF's competition here
ARTH vs HBMHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, HBMHF has a market cap of 1.4B. Regarding current trading prices, ARTH is priced at $0.00, while HBMHF trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas HBMHF's P/E ratio is 53.35. In terms of profitability, ARTH's ROE is +0.89%, compared to HBMHF's ROE of +0.02%. Regarding short-term risk, ARTH is more volatile compared to HBMHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check HBMHF's competition here
ARTH vs ASCLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ASCLF has a market cap of 1.3B. Regarding current trading prices, ARTH is priced at $0.00, while ASCLF trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ASCLF's P/E ratio is -34.50. In terms of profitability, ARTH's ROE is +0.89%, compared to ASCLF's ROE of -0.09%. Regarding short-term risk, ARTH is more volatile compared to ASCLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ASCLF's competition here
ARTH vs BRAXF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BRAXF has a market cap of 1.3B. Regarding current trading prices, ARTH is priced at $0.00, while BRAXF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BRAXF's P/E ratio is -0.03. In terms of profitability, ARTH's ROE is +0.89%, compared to BRAXF's ROE of -2.49%. Regarding short-term risk, ARTH is more volatile compared to BRAXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BRAXF's competition here
ARTH vs SNBIF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SNBIF has a market cap of 1B. Regarding current trading prices, ARTH is priced at $0.00, while SNBIF trades at $14.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SNBIF's P/E ratio is -34.83. In terms of profitability, ARTH's ROE is +0.89%, compared to SNBIF's ROE of -0.92%. Regarding short-term risk, ARTH is more volatile compared to SNBIF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SNBIF's competition here
ARTH vs BTTAY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BTTAY has a market cap of 958.8M. Regarding current trading prices, ARTH is priced at $0.00, while BTTAY trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BTTAY's P/E ratio is -67.31. In terms of profitability, ARTH's ROE is +0.89%, compared to BTTAY's ROE of +0.05%. Regarding short-term risk, ARTH is more volatile compared to BTTAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BTTAY's competition here
ARTH vs CSPHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CSPHF has a market cap of 910.9M. Regarding current trading prices, ARTH is priced at $0.00, while CSPHF trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CSPHF's P/E ratio is -62.50. In terms of profitability, ARTH's ROE is +0.89%, compared to CSPHF's ROE of -0.14%. Regarding short-term risk, ARTH is more volatile compared to CSPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CSPHF's competition here
ARTH vs BPMUF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BPMUF has a market cap of 831.5M. Regarding current trading prices, ARTH is priced at $0.00, while BPMUF trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BPMUF's P/E ratio is 9.36. In terms of profitability, ARTH's ROE is +0.89%, compared to BPMUF's ROE of -0.01%. Regarding short-term risk, ARTH is more volatile compared to BPMUF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BPMUF's competition here
ARTH vs IDRSF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, IDRSF has a market cap of 808.1M. Regarding current trading prices, ARTH is priced at $0.00, while IDRSF trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas IDRSF's P/E ratio is -2.14. In terms of profitability, ARTH's ROE is +0.89%, compared to IDRSF's ROE of +0.20%. Regarding short-term risk, ARTH is more volatile compared to IDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check IDRSF's competition here
ARTH vs PHGUF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PHGUF has a market cap of 787.9M. Regarding current trading prices, ARTH is priced at $0.00, while PHGUF trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PHGUF's P/E ratio is -57.50. In terms of profitability, ARTH's ROE is +0.89%, compared to PHGUF's ROE of -0.06%. Regarding short-term risk, ARTH is more volatile compared to PHGUF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PHGUF's competition here
ARTH vs INRLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, INRLF has a market cap of 651.3M. Regarding current trading prices, ARTH is priced at $0.00, while INRLF trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas INRLF's P/E ratio is -5.89. In terms of profitability, ARTH's ROE is +0.89%, compared to INRLF's ROE of -0.43%. Regarding short-term risk, ARTH is more volatile compared to INRLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check INRLF's competition here
ARTH vs SOLTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SOLTF has a market cap of 561.1M. Regarding current trading prices, ARTH is priced at $0.00, while SOLTF trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SOLTF's P/E ratio is -36.47. In terms of profitability, ARTH's ROE is +0.89%, compared to SOLTF's ROE of -0.07%. Regarding short-term risk, ARTH is more volatile compared to SOLTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SOLTF's competition here
ARTH vs CKDXF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CKDXF has a market cap of 474.7M. Regarding current trading prices, ARTH is priced at $0.00, while CKDXF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CKDXF's P/E ratio is -1.26. In terms of profitability, ARTH's ROE is +0.89%, compared to CKDXF's ROE of +2.04%. Regarding short-term risk, ARTH is more volatile compared to CKDXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CKDXF's competition here
ARTH vs RAONF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, RAONF has a market cap of 451.7M. Regarding current trading prices, ARTH is priced at $0.00, while RAONF trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas RAONF's P/E ratio is -43.33. In terms of profitability, ARTH's ROE is +0.89%, compared to RAONF's ROE of -0.71%. Regarding short-term risk, ARTH is more volatile compared to RAONF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check RAONF's competition here
ARTH vs TBGNF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, TBGNF has a market cap of 433.7M. Regarding current trading prices, ARTH is priced at $0.00, while TBGNF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas TBGNF's P/E ratio is -0.25. In terms of profitability, ARTH's ROE is +0.89%, compared to TBGNF's ROE of N/A. Regarding short-term risk, ARTH is more volatile compared to TBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check TBGNF's competition here
ARTH vs PTCHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PTCHF has a market cap of 425.2M. Regarding current trading prices, ARTH is priced at $0.00, while PTCHF trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PTCHF's P/E ratio is 8.43. In terms of profitability, ARTH's ROE is +0.89%, compared to PTCHF's ROE of +0.15%. Regarding short-term risk, ARTH is more volatile compared to PTCHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PTCHF's competition here
ARTH vs CLVLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CLVLF has a market cap of 401M. Regarding current trading prices, ARTH is priced at $0.00, while CLVLF trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CLVLF's P/E ratio is 16.00. In terms of profitability, ARTH's ROE is +0.89%, compared to CLVLF's ROE of +0.19%. Regarding short-term risk, ARTH is more volatile compared to CLVLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CLVLF's competition here
ARTH vs CLVLY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CLVLY has a market cap of 396M. Regarding current trading prices, ARTH is priced at $0.00, while CLVLY trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CLVLY's P/E ratio is 15.80. In terms of profitability, ARTH's ROE is +0.89%, compared to CLVLY's ROE of +0.19%. Regarding short-term risk, ARTH is more volatile compared to CLVLY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CLVLY's competition here
ARTH vs VBIZF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, VBIZF has a market cap of 393.2M. Regarding current trading prices, ARTH is priced at $0.00, while VBIZF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas VBIZF's P/E ratio is 18.90. In terms of profitability, ARTH's ROE is +0.89%, compared to VBIZF's ROE of -0.00%. Regarding short-term risk, ARTH is more volatile compared to VBIZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check VBIZF's competition here
ARTH vs HLOSF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, HLOSF has a market cap of 376M. Regarding current trading prices, ARTH is priced at $0.00, while HLOSF trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas HLOSF's P/E ratio is -11.08. In terms of profitability, ARTH's ROE is +0.89%, compared to HLOSF's ROE of -1.30%. Regarding short-term risk, ARTH is more volatile compared to HLOSF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check HLOSF's competition here
ARTH vs NWBO Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, NWBO has a market cap of 370.1M. Regarding current trading prices, ARTH is priced at $0.00, while NWBO trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas NWBO's P/E ratio is -4.23. In terms of profitability, ARTH's ROE is +0.89%, compared to NWBO's ROE of +1.13%. Regarding short-term risk, ARTH is more volatile compared to NWBO. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check NWBO's competition here
ARTH vs CYDY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CYDY has a market cap of 366.7M. Regarding current trading prices, ARTH is priced at $0.00, while CYDY trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CYDY's P/E ratio is -14.65. In terms of profitability, ARTH's ROE is +0.89%, compared to CYDY's ROE of +0.07%. Regarding short-term risk, ARTH is more volatile compared to CYDY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CYDY's competition here
ARTH vs IVEVF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, IVEVF has a market cap of 317.2M. Regarding current trading prices, ARTH is priced at $0.00, while IVEVF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas IVEVF's P/E ratio is -0.66. In terms of profitability, ARTH's ROE is +0.89%, compared to IVEVF's ROE of +1.67%. Regarding short-term risk, ARTH is more volatile compared to IVEVF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check IVEVF's competition here
ARTH vs FGHQF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, FGHQF has a market cap of 305M. Regarding current trading prices, ARTH is priced at $0.00, while FGHQF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas FGHQF's P/E ratio is 14.98. In terms of profitability, ARTH's ROE is +0.89%, compared to FGHQF's ROE of +0.00%. Regarding short-term risk, ARTH is more volatile compared to FGHQF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check FGHQF's competition here
ARTH vs PBBIF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PBBIF has a market cap of 286.9M. Regarding current trading prices, ARTH is priced at $0.00, while PBBIF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PBBIF's P/E ratio is 266.67. In terms of profitability, ARTH's ROE is +0.89%, compared to PBBIF's ROE of +0.01%. Regarding short-term risk, ARTH is more volatile compared to PBBIF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PBBIF's competition here
ARTH vs PRRUF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PRRUF has a market cap of 278.9M. Regarding current trading prices, ARTH is priced at $0.00, while PRRUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PRRUF's P/E ratio is -9.50. In terms of profitability, ARTH's ROE is +0.89%, compared to PRRUF's ROE of -0.28%. Regarding short-term risk, ARTH is more volatile compared to PRRUF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PRRUF's competition here
ARTH vs BXPHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BXPHF has a market cap of 277.1M. Regarding current trading prices, ARTH is priced at $0.00, while BXPHF trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BXPHF's P/E ratio is -14.13. In terms of profitability, ARTH's ROE is +0.89%, compared to BXPHF's ROE of -0.18%. Regarding short-term risk, ARTH is more volatile compared to BXPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BXPHF's competition here
ARTH vs CLTEF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CLTEF has a market cap of 267.4M. Regarding current trading prices, ARTH is priced at $0.00, while CLTEF trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CLTEF's P/E ratio is -3.74. In terms of profitability, ARTH's ROE is +0.89%, compared to CLTEF's ROE of -0.43%. Regarding short-term risk, ARTH is more volatile compared to CLTEF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CLTEF's competition here
ARTH vs AVCTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, AVCTF has a market cap of 257.8M. Regarding current trading prices, ARTH is priced at $0.00, while AVCTF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas AVCTF's P/E ratio is -5.84. In terms of profitability, ARTH's ROE is +0.89%, compared to AVCTF's ROE of -1.24%. Regarding short-term risk, ARTH is more volatile compared to AVCTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check AVCTF's competition here
ARTH vs ORYZF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ORYZF has a market cap of 254.2M. Regarding current trading prices, ARTH is priced at $0.00, while ORYZF trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ORYZF's P/E ratio is -46.86. In terms of profitability, ARTH's ROE is +0.89%, compared to ORYZF's ROE of -0.05%. Regarding short-term risk, ARTH is more volatile compared to ORYZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ORYZF's competition here
ARTH vs JWCTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, JWCTF has a market cap of 238.3M. Regarding current trading prices, ARTH is priced at $0.00, while JWCTF trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas JWCTF's P/E ratio is -2.94. In terms of profitability, ARTH's ROE is +0.89%, compared to JWCTF's ROE of -0.47%. Regarding short-term risk, ARTH is more volatile compared to JWCTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check JWCTF's competition here
ARTH vs SPHDF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SPHDF has a market cap of 237.9M. Regarding current trading prices, ARTH is priced at $0.00, while SPHDF trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SPHDF's P/E ratio is -4.01. In terms of profitability, ARTH's ROE is +0.89%, compared to SPHDF's ROE of +0.89%. Regarding short-term risk, ARTH is more volatile compared to SPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SPHDF's competition here
ARTH vs HNSBF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, HNSBF has a market cap of 232.3M. Regarding current trading prices, ARTH is priced at $0.00, while HNSBF trades at $2.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas HNSBF's P/E ratio is -3.08. In terms of profitability, ARTH's ROE is +0.89%, compared to HNSBF's ROE of +1.43%. Regarding short-term risk, ARTH is more volatile compared to HNSBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check HNSBF's competition here
ARTH vs NWPHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, NWPHF has a market cap of 231.2M. Regarding current trading prices, ARTH is priced at $0.00, while NWPHF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas NWPHF's P/E ratio is N/A. In terms of profitability, ARTH's ROE is +0.89%, compared to NWPHF's ROE of N/A. Regarding short-term risk, ARTH is more volatile compared to NWPHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check NWPHF's competition here
ARTH vs MDCLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, MDCLF has a market cap of 230.7M. Regarding current trading prices, ARTH is priced at $0.00, while MDCLF trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas MDCLF's P/E ratio is -5.21. In terms of profitability, ARTH's ROE is +0.89%, compared to MDCLF's ROE of +0.60%. Regarding short-term risk, ARTH is more volatile compared to MDCLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check MDCLF's competition here
ARTH vs SLNCF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SLNCF has a market cap of 226.7M. Regarding current trading prices, ARTH is priced at $0.00, while SLNCF trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SLNCF's P/E ratio is -3.14. In terms of profitability, ARTH's ROE is +0.89%, compared to SLNCF's ROE of -0.87%. Regarding short-term risk, ARTH is more volatile compared to SLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SLNCF's competition here
ARTH vs CMVLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CMVLF has a market cap of 224.9M. Regarding current trading prices, ARTH is priced at $0.00, while CMVLF trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CMVLF's P/E ratio is -4.66. In terms of profitability, ARTH's ROE is +0.89%, compared to CMVLF's ROE of -0.46%. Regarding short-term risk, ARTH is more volatile compared to CMVLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CMVLF's competition here
ARTH vs BOVNF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BOVNF has a market cap of 216.4M. Regarding current trading prices, ARTH is priced at $0.00, while BOVNF trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BOVNF's P/E ratio is -4.44. In terms of profitability, ARTH's ROE is +0.89%, compared to BOVNF's ROE of -0.50%. Regarding short-term risk, ARTH is more volatile compared to BOVNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BOVNF's competition here
ARTH vs FPHAF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, FPHAF has a market cap of 209.5M. Regarding current trading prices, ARTH is priced at $0.00, while FPHAF trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas FPHAF's P/E ratio is -7.50. In terms of profitability, ARTH's ROE is +0.89%, compared to FPHAF's ROE of N/A. Regarding short-term risk, ARTH is more volatile compared to FPHAF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check FPHAF's competition here
ARTH vs VSBC Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, VSBC has a market cap of 207M. Regarding current trading prices, ARTH is priced at $0.00, while VSBC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas VSBC's P/E ratio is N/A. In terms of profitability, ARTH's ROE is +0.89%, compared to VSBC's ROE of +0.00%. Regarding short-term risk, ARTH is more volatile compared to VSBC. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check VSBC's competition here
ARTH vs GNFTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, GNFTF has a market cap of 185.2M. Regarding current trading prices, ARTH is priced at $0.00, while GNFTF trades at $3.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas GNFTF's P/E ratio is 124.00. In terms of profitability, ARTH's ROE is +0.89%, compared to GNFTF's ROE of +0.27%. Regarding short-term risk, ARTH is more volatile compared to GNFTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check GNFTF's competition here
ARTH vs CAIHF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, CAIHF has a market cap of 183.9M. Regarding current trading prices, ARTH is priced at $0.00, while CAIHF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas CAIHF's P/E ratio is 7.00. In terms of profitability, ARTH's ROE is +0.89%, compared to CAIHF's ROE of +0.05%. Regarding short-term risk, ARTH is more volatile compared to CAIHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check CAIHF's competition here
ARTH vs BSEM Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BSEM has a market cap of 182.8M. Regarding current trading prices, ARTH is priced at $0.00, while BSEM trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BSEM's P/E ratio is 7.61. In terms of profitability, ARTH's ROE is +0.89%, compared to BSEM's ROE of +1.50%. Regarding short-term risk, ARTH is more volatile compared to BSEM. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BSEM's competition here
ARTH vs NGENF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, NGENF has a market cap of 178.9M. Regarding current trading prices, ARTH is priced at $0.00, while NGENF trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas NGENF's P/E ratio is -8.76. In terms of profitability, ARTH's ROE is +0.89%, compared to NGENF's ROE of -4.00%. Regarding short-term risk, ARTH is more volatile compared to NGENF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check NGENF's competition here
ARTH vs BRIBF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, BRIBF has a market cap of 176.1M. Regarding current trading prices, ARTH is priced at $0.00, while BRIBF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas BRIBF's P/E ratio is -2.41. In terms of profitability, ARTH's ROE is +0.89%, compared to BRIBF's ROE of -0.10%. Regarding short-term risk, ARTH is more volatile compared to BRIBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check BRIBF's competition here
ARTH vs ADOCY Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ADOCY has a market cap of 170.4M. Regarding current trading prices, ARTH is priced at $0.00, while ADOCY trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ADOCY's P/E ratio is -3.36. In terms of profitability, ARTH's ROE is +0.89%, compared to ADOCY's ROE of +1.73%. Regarding short-term risk, ARTH is more volatile compared to ADOCY. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ADOCY's competition here
ARTH vs OPORF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, OPORF has a market cap of 164.9M. Regarding current trading prices, ARTH is priced at $0.00, while OPORF trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas OPORF's P/E ratio is 12.00. In terms of profitability, ARTH's ROE is +0.89%, compared to OPORF's ROE of +0.42%. Regarding short-term risk, ARTH is more volatile compared to OPORF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check OPORF's competition here
ARTH vs MLLCF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, MLLCF has a market cap of 155.6M. Regarding current trading prices, ARTH is priced at $0.00, while MLLCF trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas MLLCF's P/E ratio is -1.98. In terms of profitability, ARTH's ROE is +0.89%, compared to MLLCF's ROE of -0.42%. Regarding short-term risk, ARTH is more volatile compared to MLLCF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check MLLCF's competition here
ARTH vs SCNLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, SCNLF has a market cap of 150.5M. Regarding current trading prices, ARTH is priced at $0.00, while SCNLF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas SCNLF's P/E ratio is -4.83. In terms of profitability, ARTH's ROE is +0.89%, compared to SCNLF's ROE of +2.45%. Regarding short-term risk, ARTH is more volatile compared to SCNLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check SCNLF's competition here
ARTH vs AAPGV Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, AAPGV has a market cap of 127.3M. Regarding current trading prices, ARTH is priced at $0.00, while AAPGV trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas AAPGV's P/E ratio is N/A. In terms of profitability, ARTH's ROE is +0.89%, compared to AAPGV's ROE of -2.50%. Regarding short-term risk, ARTH is more volatile compared to AAPGV. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check AAPGV's competition here
ARTH vs AMGXF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, AMGXF has a market cap of 127.1M. Regarding current trading prices, ARTH is priced at $0.00, while AMGXF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas AMGXF's P/E ratio is -0.46. In terms of profitability, ARTH's ROE is +0.89%, compared to AMGXF's ROE of -0.24%. Regarding short-term risk, ARTH is more volatile compared to AMGXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check AMGXF's competition here
ARTH vs IPHYF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, IPHYF has a market cap of 120.7M. Regarding current trading prices, ARTH is priced at $0.00, while IPHYF trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas IPHYF's P/E ratio is -1.85. In terms of profitability, ARTH's ROE is +0.89%, compared to IPHYF's ROE of -1.81%. Regarding short-term risk, ARTH is more volatile compared to IPHYF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check IPHYF's competition here
ARTH vs PSTTF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PSTTF has a market cap of 117.5M. Regarding current trading prices, ARTH is priced at $0.00, while PSTTF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PSTTF's P/E ratio is -29.00. In terms of profitability, ARTH's ROE is +0.89%, compared to PSTTF's ROE of N/A. Regarding short-term risk, ARTH is more volatile compared to PSTTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PSTTF's competition here
ARTH vs PPCB Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PPCB has a market cap of 111.5M. Regarding current trading prices, ARTH is priced at $0.00, while PPCB trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PPCB's P/E ratio is -0.03. In terms of profitability, ARTH's ROE is +0.89%, compared to PPCB's ROE of -36.52%. Regarding short-term risk, ARTH is more volatile compared to PPCB. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PPCB's competition here
ARTH vs HAVLF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, HAVLF has a market cap of 111.2M. Regarding current trading prices, ARTH is priced at $0.00, while HAVLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas HAVLF's P/E ratio is N/A. In terms of profitability, ARTH's ROE is +0.89%, compared to HAVLF's ROE of +0.00%. Regarding short-term risk, ARTH is more volatile compared to HAVLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check HAVLF's competition here
ARTH vs EPRXF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, EPRXF has a market cap of 108.3M. Regarding current trading prices, ARTH is priced at $0.00, while EPRXF trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas EPRXF's P/E ratio is -2.69. In terms of profitability, ARTH's ROE is +0.89%, compared to EPRXF's ROE of -0.85%. Regarding short-term risk, ARTH is more volatile compared to EPRXF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check EPRXF's competition here
ARTH vs ADOIF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, ADOIF has a market cap of 103.7M. Regarding current trading prices, ARTH is priced at $0.00, while ADOIF trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas ADOIF's P/E ratio is -2.59. In terms of profitability, ARTH's ROE is +0.89%, compared to ADOIF's ROE of +6.08%. Regarding short-term risk, ARTH is more volatile compared to ADOIF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check ADOIF's competition here
ARTH vs TRGNF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, TRGNF has a market cap of 92.7M. Regarding current trading prices, ARTH is priced at $0.00, while TRGNF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas TRGNF's P/E ratio is -2.06. In terms of profitability, ARTH's ROE is +0.89%, compared to TRGNF's ROE of -3.14%. Regarding short-term risk, ARTH is more volatile compared to TRGNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check TRGNF's competition here
ARTH vs PBIGF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, PBIGF has a market cap of 90.9M. Regarding current trading prices, ARTH is priced at $0.00, while PBIGF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas PBIGF's P/E ratio is -7.62. In terms of profitability, ARTH's ROE is +0.89%, compared to PBIGF's ROE of -2.16%. Regarding short-term risk, ARTH is more volatile compared to PBIGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check PBIGF's competition here
ARTH vs MCURF Comparison August 2025
ARTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARTH stands at 444. In comparison, MCURF has a market cap of 86.5M. Regarding current trading prices, ARTH is priced at $0.00, while MCURF trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARTH currently has a P/E ratio of -0.00, whereas MCURF's P/E ratio is -16.90. In terms of profitability, ARTH's ROE is +0.89%, compared to MCURF's ROE of -1.02%. Regarding short-term risk, ARTH is more volatile compared to MCURF. This indicates potentially higher risk in terms of short-term price fluctuations for ARTH.Check MCURF's competition here